최보현 교수

최보현 교수 이미지

학과
약리학
전문분야
종양대사, 항암제내성 약리
이메일
bchoi@cu.ac.kr
  • 학력사항

     2013-2017

    Ph.D. in Pharmacology/Pharmacokinetics, Department of Pharmacy

    The Catholic University of Korea, Korea 

     

     

     2010-2012

    M.S. in Pharmacology, Department of Pharmacy

    Yeungnam University, Korea

     

     

     2006-2010

    B.S. in Pharmacy

    Yeungnam University, Korea

     

  • 경력사항

     2020.9-present

    Assistant Professor

    Department of Pharmacology, School of Medicine, Daegu Catholic University, Korea

     

     

     2018-2020

    Postdoctoral Research Associate

    Department of Physiology and Biophysics, College of Medicine, 

    University of Illinois at Chicago, USA 

     

     

     2017-2018

    Postdoctoral Research Associate

    Department of Pharmacology, The Catholic University of Korea, Korea

     ​
  • 학회활동

    대한약리학회 국제교류위원회/IUPHAR 준비위원회 부위원장

    대한약리학회 학술위원회 학술위원

    한국응용약물학회 정보관리위원회 위원

    대한약학회 정회원

    American Association for Cancer Research(AACR) Membership

  • 주요논문

    1.   Choi BH, Rawat V, Högström J, Burns PA, Conger KO, Ozgurses ME, Patel JM, Mehta TS, Warren A, Selfors LM, Muranen T, Coloff JL. Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors. Cell Rep. 2022 Jan 18;38(3):110278.

    2.   Choi BH, Ryoo IG, Sim KH, Ahn HJ, Lee YJ, Kwak MK. High Levels of Hyaluronic Acid Synthase-2 Mediate NRF2-Driven Chemoresistance in Breast Cancer Cells. Biomol Ther (Seoul). 2022 Jul 1;30(4):368-379

    3.   Shim K, Shu M, Kim S, Kim J, Choi B, Lee Y. Cilostazol Induces Apoptosis and Inhibits Proliferation of Hepatocellular Carcinoma Cells by Activating AMPK. Biotechnology and Bioprocess Engineering. 2021 Nov; 26:776-785.

    4.  Choi BH, Kim JM, Kwak MK. The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance. Arch Pharm Res. 2021 Mar;44(3):263-280

    5.   Kim SK, Kim G, Choi BH, Ryu D, Ku SK, Kwak MK. Negative correlation of urinary miR-199a-3p level with ameliorating effects of sarpogrelate and cilostazol in hypertensive diabetic nephropathy. Biochem Pharmacol. 2021 Feb;184:114391.

    6.     Kang YP, Falzone A, Liu M, González-Sánchez P, Choi BH, Coloff JL, Saller JJ, Karreth FA, DeNicola GM. PHGDH supports liver ceramide synthesis and sustains lipid homeostasis. Cancer Metab. 2020;8:6. 

    7.    Choi BH, Coloff JL, The Diverse Functions of Non-Essential Amino Acids in Cancer, Cancers (Basel), 2019 May 15;11(5)

    8.    Choi BH*, Kim D*, Ryoo IG, Kwak MK. High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase-positive ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling. Cell death & disease. 2018 Aug 30;9(9):896 (* co-first author)

    9.     Ryoo IG, Choi BH, Ku SK, Kwak MK. High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: implications for cancer stem cell resistance. Redox Biol. 2018 Apr 26;17:246-258

    10.  Choi BH, Ryu DY, Ryoo IG, Kwak MK. NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells. Oncotarget. 2017 Nov 18;8(63):107188-107205.

    11.  Park JH*, Choi BH*, Ku SK, Kim DH, Jung KA, Oh E, Kwak MK.  Amelioration of high fat diet-induced nephropathy by cilostazol and rosuvastatin, Archives of Pharmacal Research, 2017 Jan (* co-first author)

    12.  Ryoo IG, Kim G, Choi BH, Lee SH, Kwak MK. Involvement of NRF2 Signaling in Doxorubicin Resistance of Cancer Stem Cell-Enriched Colonospheres, Biomol Ther (Seoul). 2016 Sep 1; 24(5):482-8.

    13.  Choi BH, Kwak MK. Shadows of NRF2 in cancer: Resistance to chemotherapy. Current Opinion in Toxicology, 2016 Dec; 1:20-28.

    14.  Kim DH*, Choi BH*, Ku SK, Park JH, Oh E, Kwak MK. Beneficial Effects of Sarpogrelate and Rosuvastatin in High Fat Diet/Streptozotocin-Induced Nephropathy in Mice. PLoS One. 2016 Apr; 11(4):e0153965. (* co-first author)

    15.  Song MG, Ryoo IG, Choi HY, Choi BH, Kim ST, Heo TH, Lee JY, Park PH, Kwak MK. NRF2 Signaling Negatively Regulates Phorbol-12-Myristate-13-Acetate (PMA)-Induced Differentiation of Human Monocytic U937 Cells into Pro-Inflammatory Macrophages, PLoS One. 2015 Jul 29; 10(7):e0134235.

    16.  Ryoo IG, Choi BH, Kwak MK. Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells. Oncotarget. 2015 Apr 10; 6(10): 8167-84.

    17.  Jung KA*, Choi BH*, Kwak MK. The c-MET/PI3K Signaling Is Associated with Cancer Resistance to Doxorubicin and Photodynamic Therapy by Elevating BCRP/ABCG2 Expression. Mol Pharmacol. 2015 Mar;87(3):465-76. (* co-first author)

    18.  Choi BH, Ryoo IG, Kang HC, Kwak MK. The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing. PLoS One. 2014 Sep 16;9(9):e107158.

    19.  Choi BH, Kang KS, Kwak MK. Effect of redox modulating NRF2 activators on chronic kidney disease. Molecules. 2014 Aug 20;19(8):12727-59.

    20.  Jung KA*, Choi BH*, Nam CW, Song M, Kim ST, Lee JY, Kwak MK. Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Toxicol Lett. 2013 Mar 27;218(1):39-49. (* co-first author)

    21.  Manandhar S, Choi BH, Jung KA, Ryoo IG, Song M, Kang SJ, Choi HG, Kim JA, Park PH, Kwak MK. Nrf2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: Implications for tumor growth retardation and docetaxel sensitivity, Free Radic Biol Med. 2012 May 1;52(9):1773-85